The latest announcement is out from Alzamend Neuro (ALZN).
Alzamend Neuro, Inc. has secured a significant investment deal with a sophisticated investor involving the sale of Series A Convertible Preferred Stock and Warrants, potentially injecting up to $25 million into the company. The deal, structured in multiple tranches, is contingent upon customary closing conditions, regulatory and shareholder approvals, as well as the company meeting certain milestones. Investors are granted rights such as first refusal on future investments and the ability to maintain their ownership percentage in subsequent financings. This strategic move by Alzamend Neuro aims to bolster its financial position and fuel its growth, signaling a vote of confidence from the investment community in its prospects.
See more data about ALZN stock on TipRanks’ Stock Analysis page.
